A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Recruiting

Phase 3

Sponsor:

AbbVie

Code:

NCT04064827

Conditions

Chronic Kidney Disease (CKD)

Secondary Hyperparathyroidism (SHPT)

Eligibility Criteria

Sex: All

Age: 0 - 9

Healthy Volunteers: Not accepted

Interventions

Paricalcitol

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information